DKK413.60
2.78% today
Copenhagen, Apr 03, 04:59 pm CET
ISIN
DK0060336014
Symbol
NSIS B
Industry

Novonesis Target price 2025 - Analyst rating & recommendation

Novonesis Classifications & Recommendation:

Buy
68%
Hold
21%
Sell
11%

Novonesis Price Target

Target Price DKK505.18
Price DKK402.40
Potential
Number of Estimates 17
17 Analysts have issued a price target Novonesis 2026 . The average Novonesis target price is DKK505.18. This is higher than the current stock price. The highest price target is
DKK598.33 48.69%
register free of charge
, the lowest is .
A rating was issued by 19 analysts: 13 Analysts recommend Novonesis to buy, 4 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Novonesis stock has an average upside potential 2026 of . Most analysts recommend the Novonesis stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion DKK 28.59 31.79
59.75% 11.16%
EBITDA Margin 30.77% 37.48%
5.96% 21.81%
Net Margin 8.12% 16.56%
71.45% 103.98%

16 Analysts have issued a sales forecast Novonesis 2025 . The average Novonesis sales estimate is

DKK31.8b
Unlock
. This is
11.16% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
DKK32.5b 13.67%
Unlock
, the lowest is
DKK31.3b 9.62%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 DKK28.6b 59.75%
2025
DKK31.8b 11.16%
Unlock
2026
DKK34.6b 8.86%
Unlock
2027
DKK37.3b 7.71%
Unlock
2028
DKK39.9b 7.04%
Unlock
2029
DKK44.5b 11.65%
Unlock

16 Analysts have issued an Novonesis EBITDA forecast 2025. The average Novonesis EBITDA estimate is

DKK11.9b
Unlock
. This is
35.43% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
DKK12.5b 41.62%
Unlock
, the lowest is
DKK10.9b 24.02%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 DKK8.8b 50.23%
2025
DKK11.9b 35.43%
Unlock
2026
DKK13.3b 11.86%
Unlock
2027
DKK14.7b 9.95%
Unlock
2028
DKK15.9b 8.36%
Unlock

EBITDA Margin

2024 30.77% 5.96%
2025
37.48% 21.81%
Unlock
2026
38.52% 2.77%
Unlock
2027
39.32% 2.08%
Unlock
2028
39.80% 1.22%
Unlock

10 Novonesis Analysts have issued a net profit forecast 2025. The average Novonesis net profit estimate is

DKK5.3b
Unlock
. This is
129.45% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
DKK6.4b 179.06%
Unlock
, the lowest is
DKK4.7b 104.75%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 DKK2.3b 54.40%
2025
DKK5.3b 126.68%
Unlock
2026
DKK6.2b 18.07%
Unlock
2027
DKK7.4b 19.69%
Unlock
2028
DKK7.6b 1.93%
Unlock

Net Margin

2024 8.12% 71.45%
2025
16.56% 103.98%
Unlock
2026
17.96% 8.45%
Unlock
2027
19.95% 11.08%
Unlock
2028
19.00% 4.76%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share DKK 4.98 11.29
54.40% 126.71%
P/E 35.65
EV/Sales 6.26

10 Analysts have issued a Novonesis forecast for earnings per share. The average Novonesis EPS is

DKK11.29
Unlock
. This is
129.47% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
DKK13.73 179.07%
Unlock
, the lowest is
DKK10.07 104.67%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 DKK4.98 54.40%
2025
DKK11.29 126.71%
Unlock
2026
DKK13.33 18.07%
Unlock
2027
DKK15.95 19.65%
Unlock
2028
DKK16.26 1.94%
Unlock

P/E ratio

Current 81.87 120.50%
2025
35.65 56.46%
Unlock
2026
30.19 15.32%
Unlock
2027
25.22 16.46%
Unlock
2028
24.75 1.86%
Unlock

Based on analysts' sales estimates for 2025, the Novonesis stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.95 36.30%
2025
6.26 9.98%
Unlock
2026
5.75 8.14%
Unlock
2027
5.34 7.16%
Unlock
2028
4.98 6.58%
Unlock
2029
4.46 10.43%
Unlock

P/S ratio

Current 6.56 37.63%
2025
5.90 10.04%
Unlock
2026
5.42 8.14%
Unlock
2027
5.03 7.16%
Unlock
2028
4.70 6.58%
Unlock
2029
4.21 10.43%
Unlock

Current Novonesis Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
Locked
Locked Dec 08 2024
BNP PARIBAS EXANE
Locked
Locked
Locked Nov 13 2024
REDBURN ATLANTIC
Locked
Locked
Locked Nov 10 2024
DNB MARKETS
Locked
Locked
Locked Nov 06 2024
Analyst Rating Date
Locked
BERENBERG:
Locked
Locked
Dec 08 2024
Locked
BNP PARIBAS EXANE:
Locked
Locked
Nov 13 2024
Locked
REDBURN ATLANTIC:
Locked
Locked
Nov 10 2024
Locked
DNB MARKETS:
Locked
Locked
Nov 06 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today